NCT01954316View on ClinicalTrials.gov

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2021

Study Completion Date

July 22, 2021

Conditions
Advanced Cancer
Interventions
DRUG

CFI-400945

Polo-like kinase 4 (PLK4) inhibitor

Trial Locations (2)

90404

UCLA Medical Center, Santa Monica

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

The Princess Margaret Cancer Foundation

OTHER

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

University Health Network, Toronto

OTHER

NCT01954316 - A Study of CFI-400945 Fumarate in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter